GlassScriptPhysician profile
Rafic J Farah
NPI 1780760587
$114,471.00
in general payments reported to CMS, 2019-2025
15 companies · $100K in 2025
The $100K reported for 2025 was more than what 98% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $98.45 · 2023: $19.81 · 2024: $91.87 · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $57K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $13K · Consulting Fee: $12K · Food and Beverage: $2,607 · Education: $88.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $56,730.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,125.00 |
| Travel and Lodging | $13,466.45 |
| Consulting Fee | $11,848.00 |
| Food and Beverage | $2,606.58 |
| Education | $88.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $66,799.06 | 2024-2025 | |
| Incyte Corporation | $19,578.28 | 2025 | Monjuvi |
| Kite Pharma, INC. | $10,814.13 | 2025 | Yescarta |
| Celgene Corporation | $7,313.77 | 2019 | |
| Abbvie INC. | $6,289.49 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,700.00 | 2019 | |
| Sanofi US Services INC. | $1,545.75 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $206.41 | 2019-2025 | Imfinzi |
| Janssen Biotech, INC. | $105.85 | 2019 | |
| Secura Bio, INC. | $98.45 | 2020 | |
| Merck Sharp & Dohme LLC | $19.81 | 2023 | Keytruda |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafic Farah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.